Iatrogenic mitochondriopathies: A recent lesson from nucleoside/nucleotide reverse transcriptase inhibitors

Advances in Experimental Medicine and Biology

Volumn 942, Issue , 2012, Pages 347-369

  Leung, George P H ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

DNA depletion; Mitochondrial toxicity; NRTIs; Polymerase ; Reactive oxygen species

Indexed keywords

ABACAVIR; ACETYLCYSTEINE; ADEFOVIR; ADENOSINE; ALPHA TOCOPHEROL; ASCORBIC ACID; CARNITINE; CYTIDINE; DIDANOSINE; DNA DIRECTED DNA POLYMERASE GAMMA; EMTRICITABINE; ENTECAVIR; FIALURIDINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANOSINE; HYDROXYUREA; LAMIVUDINE; MITOCHONDRIAL DNA; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RIBOFLAVIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TELBIVUDINE; TENOFOVIR; THIAMINE; THYMIDINE; UBIDECARENONE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

AGE; ANEMIA; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CARDITIS; CHRONIC DRUG ADMINISTRATION; COMORBIDITY; CREATININE CLEARANCE; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TRANSPORT; DRUG WITHDRAWAL; ENERGY METABOLISM; ENERGY SUPPLYING REACTION INHIBITION; ENZYME INHIBITION; FATTY LIVER; GENETIC VARIABILITY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL DNA MUTATION; MITOCHONDRIAL TOXICITY; MUTATION; MYOPATHY; NEPHROTOXICITY; NEUROPATHIC PAIN; NEUROPATHY; NONHUMAN; OXIDATIVE STRESS; PANCREATITIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

HUMANS; MITOCHONDRIAL DISEASES; REACTIVE OXYGEN SPECIES; RISK FACTORS;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84859926207     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-2869-1_16     Document Type: Article

References (189)

1. Adani GL, Baccarani U, Risaliti A, Bresadola F, DellaRocca G, Viale P (2005) Rhabdomyolysis due to Lamivudine administration in aliver transplant recipient. Am J Transplant 5(3):634
2. Affandi JS, Price P, Imran D, Yunihastuti E, Djauzi S, Cherry CL (2008) Can we predict neuropathy risk before stavudine prescription in aresource-limited setting? AIDS Res Hum Retroviruses 24(10):1281-1284
3. Allaouchiche B, Duflo F, Cotte L, Mathon L, Chassard D (1999) Acute pancreatitis with severe lactic acidosis in an HIV infected patient on didanosine therapy. J Antimicrob Chemother 44(1):137-138
4. Al-Madhoun AS, Tjarks W, Eriksson S (2004) The role of thymidine kinases in the activation of pyrimidine nucleoside analogues. Mini Rev Med Chem 4(4):341-350
5. Amacher DE (2005) Drug-associated mitochondrial toxicity and its detection. Curr Med Chem 12(16):1829-1839
6. Amarapurkar DN (2007) Telbivudine: anew treatment for chronic hepatitis B. World J Gastroenterol 13(46): 6150-6155
7. Anderson PL, Kakuda TN, Kawle S, Fletcher CV (2003) Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 17(15):2159-2168
8. Anderson PL, Kakuda TN, Lichtenstein KA (2004) The cellular pharmacology of nucleoside-and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 38(5):743-753
9. Arnér ES, Spasokoukotskaja T, Eriksson S (1992) Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem Biophys Res Commun 188(2):712-718
10. Bailey CM, Kasiviswanathan R, Copeland WC, Anderson KS (2009) R964C mutation of DNA polymerase gamma imparts increased stavudine toxicity by decreasing nucleoside analog discrimination and impairing polymerase activity. Antimicrob Agents Chemother 53(6):2610-2612
11. Baldwin SA, Yao SY, Hyde RJ, Ng AM, Foppolo S, Barnes K, Ritzel MW, Cass CE, Young JD (2005) Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 280(16):15880-15887
12. Balzarini J (1994) Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm World Sci 16(2):113-126
13. Balzarini J, Herdewijn P, De Clercq E (1989) Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′- dideoxythymidine (d4T) and 3′-azido-2′,3′-dideoxythymidine (AZT), two potent anti-HIV compounds. J Biol Chem 264(11):6127-6133
14. Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, Morand P, Lunel-Fabiani F, Salmon-Ceron D, Piroth L, Pialoux G, Bentata M, Cacoub P, Perronne C, ANRS Hc02-Ribavic Study Team (2005) Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 40(1):47-52
15. Barile M, Valenti D, Hobbs GA, Abruzzese MF, Keilbaugh SA, Passarella S, Quagliariello E, Simpson MV (1994) Mechanisms of toxicity of 3′-azido-3′-deoxythymidine. Its interaction with adenylate kinase. Biochem Pharmacol 48(7):1405-1412
16. Barile M, Valenti D, Passarella S, Quagliariello E (1997) 3′-Azido-3′-deoxythmidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator. Biochem Pharmacol 53(7):913-920
17. Barry M, Wild M, Veal G, Back D, Breckenridge A, Fox R, Beeching N, Nye F, Carey P, Timmins D (1994) Zidovudine phosphorylation in HIV infected patients and seronegative volunteers. AIDS 8(8):F1-F5
18. Behbahani H, Landay A, Patterson BK, Jones P, Pottage J, Agnoli M, Andersson J, Spetz AL (2000) Normalization of immune activation in lymphoid tissue following highly active antiretroviral therapy. J Acquir Immune Defic Syndr 25(2):150-156
19. Benbrik E, Chariot P, Bonavaud S, Ammi-Saïd M, Frisdal E, Rey C, Gherardi R, Barlovatz-Meimon G (1997) Cellular and mitochondrial toxicity of ziduvodine (AZT), didanosine(ddl) and zalcitabine(ddC) on cultured human cells. J Neurol Sci 149(1):19-25
20. Birkus G, Hajek M, Kramata P, Votruba I, Holy A, Otova B (2002) Tenofovir diphosphate is apoor substrate and aweak inhibitor of rat DNA polymerases alpha, delta, and epsilon. Antimicrob Agents Chemother 46(3):1610-1613
21. Birkus G, Gibbs CS, Cihlar T (2003) Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells. J Viral Hepat 10(1):50-54
22. Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cotte L, Chevallier M, Bernuau J, Lucet JC, Trepo C (1994) Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med 235(4):367-372
23. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron N, Lacroix C, Rouzioux C, Mandelbrot L, Desguerre I, Rötig A, Mayaux MJ, Delfraissy JF (1999) Persistant mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354(9184):1084-1089
24. Bolhaar MG, Karstaedt AS (2007) A high incidence of lactic acidosis and symptomatic hyperlactatemiain women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 45(2):254-260
25. Bourdais J, Biondi R, Sarfati S, Guerreiro C, Lascu I, Janin J, Véron M (1996) Cellular phosphorylation of anti-HIV nucleosides. J Biol Chem 271(14):7887-7890
26. Bremer J (1990) The role of carnitine in intracellular metabolism. J Clin Chem Clin Biochem 28(5):297-301
27. Bridges EG, Jiang Z, Cheng YC (1999) Characterization of adCTP transport activity reconstituted from human mitochondria. J Biol Chem 274(8):4620-4625
28. Brinkman K, ter Hofstede HJ (1999) Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev 1:141-148
29. Butt AA (2003) Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Read 13(7):344-348
30. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, Cooper DA, Mitochondrial Toxicity (MITOX) Study Group (2002) Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: arandomized trial. JAMA 288(2):207-215
31. Casademont J, Barrientos A, Grau JM, Pedrol E, Estivill X, Urbano-Marquez A, Nunes V (1996) The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction. Brain 119(Pt 4):1357-1364
32. Cepeda A, Wilks D (2000) Excess peripheral neuropathy in patients treated with hydroxyureaplus didanosine and stavudine for HIV infection. AIDS 14(3):332-333
33. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, Schaeffer A, Zafrani ES (1999) Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 30(1):156-160
34. Chen R, Nelson JA (2000) Role of organic cation transporters in the renal secretion of nucleosides. Biochem Pharmacol 60(2):215-219
35. Cherry CL, Gahan ME, McArthur JC, Lewin SR, Hoy JF, Wesselingh SL (2002) Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 30(3):271-277
36. Cherry CL, McArthur JC, Hoy JF, Wesselingh SL (2003) Nucleoside analogues and neuropathy in the eraof HAART. J Clin Virol 26(2):195-207
37. Cherry CL, Nolan D, James IR, McKinnon EJ, Mallal SA, Gahan ME, Lal L, McArthur JC, Wesselingh SL (2006) Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. JAcquir Immune Defic Syndr 42(4):435-440
38. Cihlar T, Ray AS, Boojamra CG, Zhang L, Hui H, Laflamme G, Vela JE, Grant D, Chen J, Myrick F, White KL, Gao Y, Lin KY, Douglas JL, Parkin NT, Carey A, Pakdaman R, Mackman RL (2008) Design and profiling of GS-9148, anovel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrob Agents Chemother 52(2):655-665
39. Collier AC, Helliwell RJ, Keelan JA, Paxton JW, Mitchell MD, Tingle MD (2003) 30-Azido-30-deoxythymidine (AZT) induces apoptosis and alters metabolic enzyme activity in human placenta. Toxicol Appl Pharmacol 192(2):164-173
40. Côté HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, OShaughnessy MV, Montaner JS (2002) Changes in mitochondrial DNA as amarker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346(11):811-820
41. Currier JS (2007) Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women. Clin Infect Dis 45(11):261-262
42. Dabis F, Ekpini ER (2002) HIV-1/AIDS and maternal and child health in Africa. Lancet 359(9323):2097-2104
43. Dagan T, Sable C, Bray J, Gerschenson M (2002) Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence. Mitochondrion 1(5):397-412
44. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL (1990) Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 322(16):1098-1105
45. Dambrova M, Liepinsh E, Kalvinsh I (2002) Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med 12(6):275-279
46. De Clercq E (2004) Discovery and development of BVDU (brivudin) as atherapeutic for the treatment of herpes zoster. Biochem Pharmacol 68(12):2301-2315
47. de la Asuncion JG, del Olmo ML, Sastre J, Millan A, Pellin A, Pallardo FV, Vina J (1998) AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest 102(1):4-9
48. Dolce V, Fiermonte G, Runswick MJ, Palmieri F, Walker JE (2001) The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc Natl Acad Sci USA 98(5):2284-2288
49. Dolin R, Amato DA, Fischl MA, Pettinelli C, Beltangady M, Liou SH, Brown MJ, Cross AP, Hirsch MS, Hardy WD, Mildvan D, Blair DC, Powderly WG, Para MF, Fife KH, Steigbigel RT, Smaldone L, AIDS Clinical Trials Group (1995) Zidovudine compared with didanosine in patients with advanced HIV-1 infection and little or no previous experience with zidovudine. Arch Intern Med 155(9):961-974
50. Domanski MJ, Sloas MM, Follmann DA, Scalise PP 3rd, Tucker EE, Egan D, Pizzo PA (1995) Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr 127(1):137-146
51. Duong Van Huyen JP, Batisse D, Heudes D, Belair MF, Piketty C, Gonzalez-Canali G, Weiss L, Kazatchkine MD, Bruneval P (2006) Alteration of cytochrome oxidase subunit I labeling is associated with severe mitochondriopathy in NRTI-related hepatotoxicity in HIV patients. Mod Pathol 19(10):1277-1288
52. Elimadi A, Morin D, Albengres E, Chauvet-Monges AM, Allain V, Crevat A, Tillement JP (1997) Differential effects of zidovudine and zidovudine triphosphate on mitochondrial permeability transition and oxidative phosphorylation. Br J Pharmacol 121(7):1295-1300
53. Esposito LA, Melov S, Panov A, Cottrell BA, Wallace DC (1999) Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci USA 96(9):4820-4825
54. Faletto MB, Miller WH, Garvey EP, St Clair MH, Daluge SM, Good SS (1997) Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 41(5):1099-1107
55. Falkenberg M, Larsson NG, Gustafsson CM (2007) DNA replication and transcription in mammalian mitochondria. Annu Rev Biochem 76:679-699
56. Famularo G, Moretti S, Marcellini S, Trinchieri V, Tzantzoglou S, Santini G, Longo A, De Simone C (1997) Acetylcarnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS 11(2):185-190
57. Fichtenbaum CJ, Clifford DB, Powderly WG (1995) Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 10(2): 169-174
58. Fleischer RD, Lok AS (2009) Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 51(4):787-791
59. Fodale V, Mazzeo A, Praticò C, Aguennouz M, Toscano A, Santamaria LB, Vita G (2005) Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage. Anaesthesia60(8): 806-810
60. Foli A, Benvenuto F, Piccinini G, Bareggi A, Cossarizza A, Lisziewicz J, Lori F (2001) Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS 15(13):1687-1694
61. Fouty B, Frerman F, Reves R (1998) Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 352(9124):291-292
62. Frank I, Bosch RJ, Fiscus S, Valentine F, Flexner C, Segal Y, Ruan P, Gulick R, Wood K, Estep S, Fox L, Nevin T, Stevens M, Eron JJ Jr, ACTG 307 Protocol Team, (2004) Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: arandomized, placebocontrolled trial, ACTG 307. AIDS Res Hum Retroviruses 20(9):916-926
63. Frick LW, Nelson DJ, St Clair MH, Furman PA, Krenitsky TA (1988) Effects of 3′-azido-3′-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells. Biochem Biophys Res Commun 154(1):124-129
64. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, Barry DW (1986) Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83(21):8333-8337
65. Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H (1993) Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 91(5): 2326-2333
66. Gao WY, Agbaria R, Driscoll JS (1994) Mitsuya H. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2,3-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 269(17): 12633-12638
67. Gattermann N, Dadak M, Hofhaus G, Wulfert M, Berneburg M, Loeffler ML, Simmonds HA (2004) Severe impairment of nucleotide synthesisthrough inhibition of mitochondrial respiration. Nucleosides Nucleotides Nucleic Acids 23(8-9):1275-1279
68. Gerschenson M, Poirier MC (2000) Fetal patas monkeys sustain mitochondrial toxicity as aresult of in utero zidovudine exposure. Ann N Y Acad Sci 918:269-281
69. Gertner E, Thurn JR, Williams DN, Simpson M, Balfour HH Jr, Rhame F, Henry K (1989) Zidovudine-associated myopathy. Am J Med 86(6 Pt 2):814-818
70. Godfried MH, van der Poll T, Jansen J, Romijin JA, Schattenkerk JK, Endert E, van Deventer SJ, Sauerwein HP (1993) Soluble receptors for tumour necrosis factor: aputative marker of disease progression in HIV infection. AIDS 7(1):33-36
71. Govindarajan R, Leung GP, Zhou M, Tse CM, Wang J, Unadkat JD (2009) Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol 296(4):G910-G922
72. Gray NM, Marr CL, Penn CR, Cameron JM, Bethell RC (1995) The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma. Biochem Pharmacol 50(7):1043-1051
73. Graziewicz MA, Longley MJ, Copeland WC (2006) DNA polymerase gammain mitochondrial DNA replication and repair. Chem Rev 106(2):383-405
74. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadée W, Amidon GL (1998) Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 15(8):1154-1159
75. Hanes JW, Johnson KA (2008) Exonuclease removal of dideoxycytidine (zalcitabine) by the human mitochondrial DNA polymerase. Antimicrob Agents Chemother 52(1):253-258
76. Hart AM, Wilson AD, Montovani C, Smith C, Johnson M, Terenghi G, Youle M (2004) Acetyl-l-carnitine: apathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 18(11):1549-1560
77. Hashimoto KI, TsunodaR, Okamoto M, Shigeta S, Baba M (1997) Stavudine selectively induces apoptosis in HIV type l-infected cells. AIDS Res Hum Retroviruses 13(2):193-199
78. Hendrickson SL, Kingsley LA, Ruiz-Pesini E, Poole JC, Jacobson LP, PalellaFJ, Bream JH, Wallace DC, OBrien SJ (2009) Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 51(2):111-116
79. Hervey PS, Perry CM (2000) Abacavir: areview of its clinical potential in patients with HIV infection. Drugs 60(2): 447-479
80. Hestdal K, Aukrust P, Müller F, Lien E, Bjerkeli V, Espevik T, Frøland SS (1997) Dysregulation of membrane-bound tumor necrosis factor-aand tumor necrosis factor receptors on mononuclear cells in human immunodeficiency virus type 1 infection: low percentage of p75-tumor necrosis factor receptor positive cells in patients with advanced disease and high viral load. Blood 90(7):2670-2679
81. Hill A, Ruxrungtham K, Hanvanich M, KatlamaC, Wolf E, Soriano V, Milinkovic A, Gatell J, RiberaE (2007) Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 8(5):679-688
82. Hoggard PG, Kewn S, Maherbe A, Wood R, Almond LM, Sales SD, Gould J, Lou Y, De Vries C, Back DJ, Khoo SH, CHARM Study Group (2002) Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. AIDS 16(18):2439-2446
83. Hsu CH, Hu R, Dutschman GE, Yang G, Krishnan P, TanakaH, Baba M, Cheng YC (2007) Comparison of the phosphorylation of 4′-ethynyl 2′,3′-dihydro-3′-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs. Antimicrob Agents Chemother 51(5):1687-1693
84. Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Kallianpur AR, Summar M, Canter JA (2005) Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS 19(13):1341-1349
85. Hulgan T, Tebas P, Canter JA, Mulligan K, Haas DW, Dubé M, Grinspoon S, Robbins GK, Motsinger AA, Kallianpur AR, AIDS Clinical Trials Group 384 and A5005s Study Teams (2008) Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis 197(6):858-866
86. ImaokaT, KusuharaH, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y (2007) Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 71(2):619-627
87. Izzedine H, Hulot JS, Launay-Vacher V, Marcellini P, Hadziyannis SJ, Currie G, Brosgart CL, Westland C, Arterbrun S, Deray G, Adefovir Dipivoxil International 437 Study Group, Adefovir Dipivoxil International 438 Study Group (2004) Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Kidney Int 66(6):1153-1158
88. Izzedine H, Harris M, Perazella MA (2009) The nephrotoxic effects of hAArT. Nat Rev Nephrol 5(10):563-573
89. Johnson MA, Fridland A (1989) Phosphorylation of 2′,3′- dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol Pharmacol 36(2):291-295
90. Jullig M, Eriksson S (2000) Mitochondrial and submitochondrial localization of human deoxyguanosine kinase. Eur J Biochem 267(17):5466-5472
91. Kakuda TN (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22(6):685-708
92. Kestens L, Vanham G, Vereecken C, Vandenbruaene M, Vercauteren G, Colebunders RL, Gigase PL (1994) Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO + T lymphocytes during HIV-1 infection. Clin Exp Immunol 95(4):436-441
93. Kewn S, Hoggard PG, Sales SD, Johnson MA, Back DJ (2000) The intracellular activation of lamivudine (3TC) and determination of 2′-deoxycytidine-5′-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells. Br J Clin Pharmacol 50(6):597-604
94. KlusaV, Pupure J, Isajevs S, Rumaks J, Gordjushina V, Kratovska A, Taivans I, Svirskis S, Viksna L, Kalvinsh I (2006) Protection of azidothymidine-induced cardiopathology in mice by mildronate, amitochondria-targeted drug. Basic Clin Pharmacol Toxicol 99(4):323-328
95. Kunkel TA, Mosbaugh DW (1989) Exonucleolytic proofreading by amammalian DNA polymerase. Biochemistry 28(3):988-995
96. Lai Y, Tse CM, Unadkat JD (2004) Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem 279(6):4490-4497
97. Lam W, Chen C, Ruan S, Leung CH, Cheng YC (2005) Expression of deoxynucleotide carrier is not associated with the mitochondrial DNA depletion caused by anti-HIV dideoxynucleoside analogs and mitochondrial dNTP uptake. Mol Pharmacol 67(2):408-416
98. Lebrecht D, Deveaud C, Beauvoit B, Bonnet J, Kirschner J, Walker UA (2008) Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemiain mice. Arthritis Rheum 58(1):318-326
99. Lenzo NP, Garas BA, French MA (1997) Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: acase report. AIDS 11(10):1294-1295
100. Leung S, Bendayan R (1999) Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugs. Can J Physiol Pharmacol 77(8):625-630
101. Leung GP, Tse CM (2007) The role of mitochondrial and plasmamembrane nucleoside transporters in drug toxicity. Expert Opin Drug Metab Toxicol 3(5):705-718
102. Lewis W, Dalakas MC (1995) Mitochondrial toxicity of antiviral drugs. Nat Med 1(5):417-422
103. Lewis W, Gonzalez B, Chomyn A, Papoian T (1992) Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest 89(4):1354-1360
104. Lewis W, Day BJ, Copeland WC (2003) Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2(10):812-822
105. Lewis W, Haase CP, Miller YK, Ferguson B, Stuart T, Ludaway T, McNaught J, Russ R, Steltzer J, Santoianni R, Long R, Fiermonte G, Palmieri F (2005) Transgenic expression of the deoxynucleotide carrier causes mitochondrial damage that is enhanced by NRTIs for AIDS. Lab Invest 85(8):972-981
106. Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, Bienstock RJ, Ludaway T, McNaught J, Russ R, Stuart T, Santoianni R (2006) Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gammahypothesis. AIDS 20(5):675-684
107. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD, HIV Outpatient Study Investigators (2005) Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 40(1):148-157
108. Lim SE, Copeland WC (2001) Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 276(26):23616-23623
109. Lim SE, Ponamarev MV, Longley MJ, Copeland WC (2003) Structural determinants in human DNA polymerase gammaaccount for mitochondrial toxicity from nucleoside analogs. J Mol Biol 329(1):45-57
110. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, Lai WW, Moodie DS, Sopko G, McIntosh K, Colan SD (2000) Absence of cardiac toxicity of zidovudine in infants. Pediatric pulmonary and cardiac complications of vertically transmitted HIV infection study group. N Engl J Med 343(11):759-766
111. Lonergan JT, McComsey GA, Fisher RL, Shalit P, File TM Jr, Ward DJ, Williams VC, Hessenthaler SM, Lindsey L, Hernandez JE, for the ESS40010 (TARHEEL) Study Team (2004) Lack of recurrence of hyperlactatemiain HIVinfected patients switched from stavudine to abacavir to zidovudine. J Acquir Immune Defic Syndr 36(4):935-942
112. Lund KC, Wallace KB (2004) Direct, DNA pol-gamma-independent effects of nucleoside reverse transcriptase inhibitors on mitochondrial bioenergetics. Cardiovasc Toxicol 4(3):217-228
113. Lund KC, Wallace KB (2008) Adenosine 3′,5′-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors. Toxicol Appl Pharmacol 226(1): 94-106
114. Lynx MD, LaClair DD, McKee EE (2009) Effects of zidovudine and stavudine on mitochondrial DNA of differentiating 3 T3-F442acells are not associated with imbalanced deoxynucleotide pools. Antimicrob Agents Chemother 53(3):1252-1255
115. Martin JL, Brown CE, Matthews-Davis N, Rea Rdon JE (1994) Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 38(12):2743-2749
116. Martin AM, Hammond E, Nolan D, Pace C, Den Boer M, Taylor L, Moore H, Martinez OP, Christiansen FT, Mallal S (2003) Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reversetranscriptase inhibitors. Am J Hum Genet 72(3):549-560
117. Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ (2008) Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gammainhibition. Antimicrob Agents Chemother 52(2):598-605
118. McComsey GA, Morrow JD (2003) Lipid oxidative markers are significantly increased in lipoatrophy, but not in sustained asymptomatic hyperlactatemia. J Acquir Immune Defic Syndr 34(1):45-49
119. McComsey G, Tan DJ, Lederman M, Wilson E, Wong LJ (2002) Analysis of mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with of without lipoatrophy. AIDS 16(4):513-518
120. McComsey G, Southwell H, Gripshover B, SalataR, Valdez H (2003) Effect of antioxidants on glucose metabolism and plasmalipids in HIV-infected subjects with lipoatrophy. J Acquir Immune Defic Syndr 33(5):605-607
121. McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, Fisher RL, Williams VC, Hernandez JE, Trial to Assess the Regression of Hyperlactatemiaand to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL; ESS40010) Study Team (2004) Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 38(2):263-270
122. McComsey G, Bai RK, Maa JF, Seekins D, Wong LJ (2005) Extensive investigations of mitochondrial DNA genome in treated HIV-infected subjects: beyond mitochondrial DNA depletion. J Acquir Immune Defic Syndr 39(2):181-188
123. McKee EE, Bentley AT, Hatch M, Gingerich J, Susan-ResigaD (2004) Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of anovel mechanism of AZT cardiotoxicity. Cardiovasc Toxicol 4(2):155-167
124. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka JL, Straus SE, Hoofnagle JH (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333(17):1099-1105
125. Meng Q, Grosovsky AJ, Shi X, Walker VE (2000) Mutagenicity and loss of heterozygosity at the APRT locus in human lymphoblastoid cells exposed to 3′-azido-3′-deoxythymidine. Mutagenesis 15(5):405-410
126. Merta A, Votruba I, Jindrich J, Holý A, Cihlár T, Rosenberg I, Otmar M, Herve TY (1992) Phosphorylation of 9-(2-phosphonomethoxyethyl) adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine by AMP(dAMP) kinase from L1210 cells. Biochem Pharmacol 44(10):2067-2077
127. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA (2000) Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 133(3):192-196
128. Miró O, López S, Rodríguez de laConcepción M, Martínez E, Pedrol E, Garrabou G, Giralt M, Cardellach F, Gatell JM, VilarroyaF, Casademont J (2004) Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine. J Acquir Immune Defic Syndr 37(5):1550-1555
129. Modica-Napolitano JS (1993) AZT causes tissue-specific inhibition of mitochondrial bioenergetic function. Biochem Biophys Res Commun 194(1):170-177
130. Modrzejewski KA, Herman RA (2004) Emtricitabine: aonce-daily nucleoside reverse transcriptase inhibitor. Ann Pharmacother 38(6):1006-1014
131. Mokrzycki H, Harris C, May H, Laut J, Palmisano J (2000) Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 30(1):198-200
132. Moore RD, Wong WM, Keruly JC, McArthur JC (2000) Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 14(3):273-278
133. Moreno A, QueredaC, Moreno L, Perez-Elías MJ, Muriel A, Casado JL, Antela A, Dronda F, Navas E, Bárcena R, Moreno S (2004) High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther 9(1):133-138
134. Moretti S, Famularo G, Marcellini S, Boschini A, Santini G, Trinchieri V, Lucci L, Alesse E, De Simone C (2002) L-carnitine reduces lymphocyte apoptosis and oxidative stress in HIV-1-infected subjects treated with zidovudine and didanosine. Antioxid Redox Signal 4(3):391-403
135. Morris GW, Iams TA, Slepchenko KG, McKee EE (2009) Origin of pyrimidine deoxyribonucleotide pools in perfused rat heart: implications for 3′-azido-3′-deoxythymidine-dependent cardiotoxicity. Biochem J 422(3):513-520
136. Moyle G (2000) Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 22(8):911-936
137. Moyle G (2005) Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther 10(Suppl 2):M47-M52
138. Moyle GJ, Datta D, MandaliaS, Morlese J, Asboe D, Gazzard BG (2002) Hyperlactatemiaand lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 16(10):1341-1349
139. Munch-Petersen B (1984) Differences in the kinetic properties of thymidine kinase isoenzymes in unstimulated and phytohemagglutinin-stimulated human lymphocytes. Mol Cell Biochem 64(2):173-185
140. Munch-Petersen B, Tyrsted G (1977) Induction of thymidine kinases in phytohaemagglutinin-stimulated human lymphocytes. Biochim Biophys Acta478(3):364-375
141. Negredo E, Miró O, Rodríguez-Santiago B, Garrabou G, Estany C, Masabeu A, Force L, Barrufet P, Cucurull J, Domingo P, Alonso-Villaverde C, Bonjoch A, Morén C, Pérez-Alvarez N, Clotet B, MULTINEKA Study Group (2009) Improvement of mitochondrial toxicity in patients receiving anucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra(MULTINEKA). Clin Infect Dis 49(6):892-900
142. Opii WO, Sultana R, Abdul HM, Ansari MA, Nath A, Butterfield DA (2007) Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)-2′,3′-dideoxycytidine (ddC): relevance to HIV-dementia. Exp Neurol 204(1):29-38
143. Panel on Antiretroviral Guidelines for Adults and Adolescents (2008)
144. Pan-Zhou XR, Cui L, Zhou XJ, Sommadossi JP, Darley-Usmar VM (2000) Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob Agents Chemother 44(3):496-503
145. Peltier AC, Russell JW (2006) Advances in understanding drug-induced neuropathies. Drug Saf 29(1):23-30
146. Perno CF, Cooney DA, Gao WY, Hao Z, Johns DG, Foli A, Hartman NR, Caliò R, Broder S, Yarchoan R (1992) Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Blood 80(4):995-1003
147. Ronan A, Lipman C, Johnson A, Breen RA (2000) Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals. AIDS 14(5):615-616
148. Rossi L, Serafini S, Schiavano GF, Casabianca A, Vallanti G, Chiarantini L, Magnani M (1999) Metabolism, mitochondrial uptake and toxicity of 2′,3′-dideoxycytidine. Biochem J 344(Pt 3):915-920
149. Rylova SN, Albertioni F, Flygh G, Eriksson S (2005) Activity profiles of deoxynucleoside kinases and 5′-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs. Biochem Pharmacol 69(6):951-960
150. Rylova SN, Mirzaee S, Albertioni F, Eriksson S (2007) Expression of deoxynucleoside kinases and 5′-nucleotidases in mouse tissues: implications for mitochondrial toxicity. Biochem Pharmacol 74(1):169-175
151. Sakamoto S, IwamaT, TsukadaK, UtsunomiyaJ, Kawasaki T, Okamoto R (1984) Increased activity of thymidine kinase isozyme in human colon tumor. Carcinogenesis 5(2):183-185
152. Sales SD, Hoggard PG, Sunderland D, Khoo S, Hart CA, Back DJ (2001) Zidovudine phosphorylation and mitochondrial toxicity in vitro. Toxicol Appl Pharmacol 177(1):54-58
153. Scadden DT, Pickus O, Hammer SM, Stretcher B, Bresnahan J, Gere J, McGrath J, Agosti JM (1996) Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 12(12):1151-1159
154. Schramm C, Wanitschke R, Galle PR (1999) Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. Eur J Anaesthesiol 16(10):733-735
155. Semino-Mora MC, Leon-Monzon ME, Dalakas MC (1994) Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part II: Treatment with L-carnitine improves AZTinduced changes and prevents further destruction. Lab Invest 71(5):773-781
156. Setzer B, Lebrecht D, Walker UA (2008) Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine. Am J Pathol 172(3):681-690
157. Shaer AJ, Rastegar A (2000) Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome. A case report and review of the literature. Am J Nephrol 20(4):332-338
158. Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, Shiramizu B (2001) Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 15(14):1801-1809
159. Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson M, Erdem G, Pinti M, Cossarizza A, Shikuma C (2003) Placentaand cord blood mitochondrial DNA toxicity in HIV-infected women receiving HAART during pregnancy. J Acquir Immune Defic Syndr 32(4):370-374
160. Skuta G, Fischer GM, Janaky T, Kele Z, Szabo P, Tozser J, Sumegi B (1999) Molecular mechanism of the short-term cardiotoxicity caused by 2′,3′-dideoxycytidine (ddC): modulation of reactive oxygen species levels and ADPribosylation reactions. Biochem Pharmacol 58(12):1915-1925
161. Smyth K, Affandi JS, McArthur JC, Bowtell-Harris C, Mijch AM, Watson K, Costello K, Woolley IJ, Price P, Wesselingh SL, Cherry CL (2007) Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia1993-2006. HIV Med 8(6):367-373
162. Song S, Pursell ZF, Copeland WC, Longley MJ, Kunkel TA, Mathews CK (2005) DNA precursor asymmetries in mammalian tissue mitochondriaand possible contribution to mutagenesis through reduced replication fidelity. Proc Natl Acad Sci USA 102(14):4990-4995
163. Sussman HE, Olivero OA, Meng Q, Pietras SM, Poirier MC, ONeill JP, Finette BA, Bauer MJ, Walker VE (1999) Genotoxicity of 3′-azido-3′- deoxythymidine in the human lymphoblastoid cell line, TK6: relationships between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT. Mutat Res 429(2):249-259
164. Szabados E, Fischer GM, Toth K, Csete B, Nemeti B, Trombitas K, Habon T, Endrei D, Sumegi B (1999) Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. Free Radic Biol Med 26(3-4):309-317
165. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, Dagati VD (2001) Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 32(7):734-740
166. Tesco G, Latorraca S, Piersanti P, Piacentini S, Amaducci L, Sorbi S (1992) Protection from oxygen radical damage in human diploid fibroblasts by acetyl-L-carnitine. Dementia3:58-60
167. Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science 281(5381):1312-1316
168. Tsai CH, Doong SL, Johns DG, Driscoll JS, Cheng YC (1994) Effect of anti-HIV 2′-beta-fluoro-2′,3′-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production. Biochem Pharmacol 48(7): 1477-1481
169. Tuon FF, Guastini CM, Boulos MI (2008) Acute pancreatitis associated with lamivudine therapy for chronic B hepatitis. Braz J Infect Dis 12(4):263
170. Turriziani O, ButeraO, Gianotti N, Parisi SG, Mazzi R, Girardi E, Iaiani G, Antonelli L, Lazzarin A, Antonelli G (2005) Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients. AIDS 19(5):473-479
171. Uwai Y, IdaH, Tsuji Y, Katsura T, Inui K (2007) Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 24(4):811-815
172. Valenti D, Barile M, Quagliariello E, Passarella S (1999) Inhibition of nucleoside diphosphate kinase in rat liver mitochondria by added 3′-azido-3′-deoxythymidine. FEBS Lett 444(2-3):291-295
173. Valenti D, Atlante A, Barile M, Passarella S (2002) Inhibition of phosphate transport in rat heart mitochondriaby 3′-azido-3′- deoxythymidine due to stimulation of superoxide anion mitochondrial production. Biochem Pharmacol 64(2):201-206
174. Velsor LW, Kovacevic M, Goldstein M, Leitner HM, Lewis W, Day BJ (2004) Mitochondrial oxidative stress in human hepatomacells exposed to stavudine. Toxicol Appl Pharmacol 199(1):10-19
175. Venhoff N, Setzer B, Melkaoui K, Walker UA (2007) Mitochondrial toxicity of tenofovir, emtricitabine, and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther 12(7):1075-1085
176. Vrouenraets SM, Treskes M, Regez RM, Troost N, Smulders YM, Weigel HM, Frissen PH, Brinkman K (2002) Hyperlactataemiain HIV-infected patients: the role of NRTI-treatment. Antivir Ther 7(4):239-244
177. Wada S, Tsuda M, Sekine T, Cha SH, Kimura M, Kanai Y, Endou H (2000) Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther 294(3): 844-849
178. Walker UA, Venhoff N (2005) Uridine in the prevention and treatment of NRTI related mitochondrial toxicity. Antivir Ther 10(supp 2):M117-M123
179. Walker UA, Setzer B, Venhoff N (2002) Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16(16):2165-2173
180. Walker UA, Bäuerle J, Laguno M, Murillas J, Mauss S, Schmutz G, Setzer B, Miquel R, Gatell JM, Mallolas J (2003) Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 39(2):311-317
181. Wallace DC (1992) Mitochondrial genetics: aparadigm for aging and degenerative diseases? Science 256(5057): 628-632
182. Wang L, Eriksson S (2003) Mitochondrial deoxyguanosine kinase mutations and mitochondrial DNA depletion syndrome. FEBS Lett 554(3):319-322
183. Ward JL, Sherali A, Mo ZP, Tse CM (2000) Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2exhibits alow affinity for guanosine and cytidine but ahigh affinity for inosine. J Biol Chem 275(12):8375-8381
184. Wiesner RJ, Ruegg JC, Morano I (1992) Counting target molecules by exponential polymerase chain reaction: copy number of mitochondrial DNA in rat tissues. Biochem Biophys Res Commun 183(2):553-559
185. Wu Y, Li N, Zhang T, Wu H, Huang C, Chen D (2009) Mitochondrial DNA base excision repair and mitochondrial DNA mutation in human hepatic HuH-7 cells exposed to stavudine. Mutat Res 664(1-2):28-38
186. YamanakaG, Wilson T, Innaimo S, Bisacchi GS, Egli P, Rinehart JK, Zahler R, Colonno RJ (1999) Metabolic studies on BMS-200475, anew antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 43(1): 190-193
187. Yamanaka H, Gatanaga H, Kosalaraksa P, Matsuoka-Aizawa S, Takahashi T, Kimura S, Oka S (2007) Novel mutation of human DNA polymerase gammaassociated with mitochondrial toxicity induced by anti-HIV treatment. J Infect Dis 195(10):1419-1425
188. Zeviani M, Di Donato S (2004) Mitochondrial disorders. Brain 127(Pt10):2153-2172
189. Zhang XS, Jin R, Zhang SB, Tao ML (2008) Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol 14(22):3549-3553